4D Molecular Therapeutics (FDMT) Cash & Equivalents (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Cash & Equivalents data on file, last reported at $72.5 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 45.71% year-over-year to $72.5 million in Q1 2026; TTM through Mar 2026 was $72.5 million, a 45.71% decrease from a year earlier, with the FY2025 full-year figure at $60.2 million, down 59.66% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $72.5 million, up from $60.2 million in the prior quarter.
• Over the last five years, Cash & Equivalents for FDMT reached as high as $275.7 million in Q3 2023 and fell as low as $48.6 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $140.2 million across 5 years, with a median of $113.5 million in 2022.
• Across the five-year window, Cash & Equivalents soared 375.84% in 2023 and plunged 74.11% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $52.4 million in 2022, then soared by 375.84% to $249.1 million in 2023, then slumped by 40.05% to $149.3 million in 2024, then sank by 59.66% to $60.2 million in 2025, then gained by 20.33% to $72.5 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $72.5 million in Q1 2026, $60.2 million in Q4 2025, and $48.6 million in Q3 2025.